Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Significance of CX3CR1 Adhesion Molecule-expressing Myeloid and Lymphoid Cells in Hematologic Malignancy

NCT02885623 is registered in ClinicalTrials.gov with Saint Vincent's Hospital, Korea as lead sponsor.

NCT NCT02885623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02885623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Significance of CX3CR1 Adhesion Molecule-expressing Myeloid and Lymphoid Cells in Hematologic Malignancy
Lead sponsor
Saint Vincent's Hospital, Korea
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2016
Completion date
August 31, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cx3cr1 protein, diffuse large b cell lymphoma, multiple myeloma